NCT05394142View on ClinicalTrials.gov

A Clinical Trial to Evaluate the Efficacy, Tolerability, and Safety of a Fixed Dose Combination of Spironolactone, Pioglitazone & Metformin (SPIOMET) in Polycystic Ovary Syndrome (PCOS)

PHASE2RecruitingINTERVENTIONAL
Enrollment

364

Participants

Timeline

Start Date

May 24, 2022

Primary Completion Date

April 30, 2025

Study Completion Date

April 30, 2025

Conditions
Polycystic Ovary Syndrome (PCOS)
Interventions
DRUG

Placebo

Comparator arm with placebo

DRUG

Pioglitazone

Pioglitazone 7.5 mg/day

DRUG

Spironolactone

Spironolactone 50 mg/day

DRUG

Metformin

Metformin 850 mg/day

Trial Locations (7)

Unknown

RECRUITING

Universitätsklinik für Innere Medizin, Graz

RECRUITING

Odense University Hospital (UNIODE), Odense

RECRUITING

Azienda Ospedaliero Universitaria di Bologna, Bologna

RECRUITING

St. Olavs Hospital, Trondheim

RECRUITING

Hospital Sant Joan de Deu, Esplugues de Llobregat

RECRUITING

Hospital Universitari de Girona Dr. Trueta, Girona

RECRUITING

İstanbul Faculty of Medicine Topkapı, Istanbul

All Listed Sponsors
lead

Fundació Sant Joan de Déu

OTHER